pbt & prr ...re: thoughts? -time for rebound Agreed.....note that PRR and Prana Biotechnology have a collaboration with the Austin Research Institute for the development of a vaccine for Alzheimer's Disease. The Austin Research Institute is an independent medical
research institute and has affiliation agreements with the University of Melbourne and Victoria University.
PRIMA BIOMED LTD [PRR]
Last Updated 18/03/2004
CORPORATE DETAILS
GICS Sector 35: Health Care
GICS Industry Group 3520: Pharmaceuticals & Biotechnology
Head Office Unit 7, 79-83 High St, Kew, VIC, 3101
Telephone (03) 9854 5700
Facsimile (03) 9854 5777
Website www.primabiomed.com.au
First Listed 23/06/1988
Balance Date 30 June
AGM 26/09/2003
Dividend Reinvestment? None
PRINCIPAL ACTIVITY
Prima Biomed Ltd (PRR) aims to identify, fund, develop and manage biotechnology
research, as to produce potential products for human and animal health care.
CANCER VAC LIMITED (65%): Cancer Vac Limited is focused on immunology
particularly in the areas of Cancer immunotherapy, Autoimmunity, Vaccines and
Xenotransplantation. An agreement has been signed with Progen Industries to
scale up manufacture of a cancer vaccine in Phase II trials.
ARTHRON LIMITED (65%): Subsidiary of Prima Biomed, Arthron is in preclinical
drug development targeting rheumatoid arthritis. Development is focused on a
closer source of rheumatoid arthritis, compared with existing drugs. Arthron has
patents surrounding the Fc receptor and has developed a data package
demonstrating that the receptor is a valid target for developing treatments for
rheumatoid arthritis. The company is in discussions to co-develop the
technology.
PANVAX LIMITED (65%): Panvax is involved in the development of vaccine
alternatives that stimulate auto immune responses that prevent parasitic
diseases and growth of tumours. The company is developing DCtag vaccine
technology that has the ability to protect animals against malaria parasites and
provide treatment against tumours in mice.
ONCOMAB LIMITED (65%): Oncomab is involved in the development and
commercialisation of anti cancer antibodies. Oncomab antibodies recognise the
tumour antigen called cripto-1 that is found in 79% of breast cancer tissues.
ALZHEIMER'S DISEASE VACCINE: PRR and Prana Biotechnology have a collaboration
with the Austin Research Institute for the development of a vaccine for
Alzheimer's Disease. The Austin Research Institute is an independent medical
research institute and has affiliation agreements with the University of
Melbourne and Victoria University.
DIRECTORS
Mr Marcus Clark
Mr Bryan John Frost
Mr Mark Hogarth
Mr Richard Revelins
PRINCIPALS
Chairman Mr Bryan John Frost
MD/CEO Mr Marcus Clark
Company Secretary Mr Phillip Hains
Mr Richard Revelins
ADVISERS
Auditors Hall Chadwick
Solicitors Oakley Thompson
Bankers n/a
REGISTRY
Name Security Transfers
Registry Address Applecross, WA,
Registry Postal Address PO Box 535, Applecross, WA, 6953
Registry Telephone (08) 9315 0933
Registry Facsimile (08) 9315 2233
Registry TollFree n/a
Investor Enquiries n/a
Broker Number n/a
Web Site n/a
SUBSTANTIAL SHAREHOLDERS -
LATEST BALANCE
Report Effect. Substantial Shareholding % Held at % Held
Date Date Shareholder Eff. Date Current
------------------------------------------------------------------------------
N/A 25/11/03 Peregrine Corporate Limited 9,734,584 14.29 14.02
30/06/03 25/09/03 Bodie Investment Pty Ltd 3,819,500 6.5 5.5
30/06/03 25/09/03 Queensland Investment 3,400,000 5.79 4.9
Corporation
Note: % Held Currently refers to the percentage held calculated based on latest
total number of shares outstanding.
BALANCES AS AT 2003 ANNUAL REPORT
Report Effect. Substantial Shareholding % Held
Date Date Shareholder Eff.Date
------------------------------------------------------------------------------
30/06/03 25/09/03 Peregrine Corporate Limited 9,984,229 17
30/06/03 25/09/03 Bodie Investment Pty Ltd 3,819,500 6.5
30/06/03 25/09/03 Queensland Investment Corporation 3,400,000 5.79
BUYS OVER LAST 12 MONTHS
Effect. Substantial Prev.% New% ShrsTraded
Date Shareholder
------------------------------------------------------------------------------
There were no buys over the last 12 months.
SELLS OVER LAST 12 MONTHS
Effect. Substantial Prev.% New% ShrsTraded
Date Shareholder
------------------------------------------------------------------------------
25/11/03 Peregrine Corporate Limited 15.24 14.29 642,145
03/10/03 Peregrine Corporate Limited 17 15.24 N/A
09/09/03 Peregrine Corporate Limited 20.32 17 276,855
26/08/03 Queensland Investment Corporation 7.55 5.87 N/A
21/08/03 Bondie Investments Ptd Ltd 9.36 6.6 N/A
21/08/03 Peregrine Strategic Ltd 20.32 17.72 N/A
01/07/03 Peregrine Strategic Ltd 22.02 20.32 854,594
- Forums
- ASX - By Stock
- IMM
- thoughts?
thoughts?, page-5
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
35.5¢ |
Change
0.015(4.41%) |
Mkt cap ! $515.6M |
Open | High | Low | Value | Volume |
34.0¢ | 36.0¢ | 33.5¢ | $1.213M | 3.471M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
42 | 1254253 | 35.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
35.5¢ | 252703 | 36 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
43 | 1264653 | 0.350 |
8 | 174021 | 0.345 |
11 | 145473 | 0.340 |
8 | 109456 | 0.335 |
12 | 190739 | 0.330 |
Price($) | Vol. | No. |
---|---|---|
0.355 | 240599 | 35 |
0.360 | 228831 | 19 |
0.365 | 144930 | 12 |
0.370 | 181435 | 7 |
0.375 | 99142 | 4 |
Last trade - 14.00pm 18/09/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |